BioSpace News Archive

Drug Development

Amgen Release: EMA Accepts Filing for EVENITY (Romosozumab)

If approved in Europe, EVENITY will be a novel osteoporosis treatment that increases bone formation and reduces bone resorption simultaneously to increase BMD and reduce the risk of fracture.

January 8, 2018
·
14 min read
Business

Effective January 15th: Perrigo CEO Retires, New Leader Named

Perrigo today announced the appointment of Uwe Rohrhoff as Chief Executive Officer, effective January 15, 2018, following the retirement of John T. Hendrickson.

January 8, 2018
·
7 min read
Business

GE, Roche Enter Partnership to Develop Integrated Digital Diagnostics Platform to Improve Oncology and Critical Care Treatment

The partnership will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.

January 8, 2018
·
4 min read
Syngenta Announces Filing for Voluntary Delisting of American Depositary Shares from NYSE

The delisting will become effective on January 18, 2018.

January 8, 2018
·
2 min read
Business

QIAGEN and DiaSorin Partner to Offer Fully Automated Tuberculosis Detection With QuantiFERON-TB Gold Plus Available on LIAISON Analyzer Systems

This addition will enable customers of both companies to process QuantiFERON-TB Gold Plus on LIAISON family platforms.

January 8, 2018
·
2 min read
BioCapital

QIAGEN Adds to Growth Momentum in Next-Generation Sequencing With 2018 Plans for Significant Portfolio Enhancements

QIAGEN has set a goal to exceed $140 million in 2018 sales from this portfolio, up from over $115 million in 2017.

January 8, 2018
·
2 min read
Business

Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with Sanofi

Evotec and Apeiron announced today that the companies received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015.

January 8, 2018
·
5 min read
ANGLE plc: Prostate Cancer ARV7 Treatment Biomarker

Measurement of the expression of ARV7 on circulating tumor cells (CTCs) obtained from a blood test1 has previously been studied and found to correlate with patient response to novel hormone therapy (NHT) drugs (Enzalutamide and Abiraterone).

January 8, 2018
·
7 min read
Drug Development

TopiVert Pharma Limited: Positive Results From TOP1288 Phase I Study

TopiVert announces positive data from its Phase 1 study (TV03) with its oral formulation of TOP1288 for the treatment of ulcerative colitis (UC).

January 8, 2018
·
6 min read
Drug Development

Medivir Release: Successful Completion of Pre-clinical Safety Studies With MIV-818, Enabling Start of Phase I Clinical Studies in 2018

Medivir AB today announced the successful completion of the pre-clinical safety studies for MIV-818 to enable the start of phase I clinical trials in 2018.

January 8, 2018
·
2 min read